Receptor News and Research

RSS

New 2025 guidelines focus on early intervention and lifestyle to manage high blood pressure

Preventing and managing high blood pressure with healthy lifestyle behaviors, such as following a heart-healthy diet including reducing salt intake, staying physically active, maintaining a healthy weight and managing stress—combined with early treatment with medication to lower blood pressure if necessary—are recommended to reduce the risk of heart attack, stroke, heart failure, kidney disease, cognitive decline and dementia, according to a new clinical guideline published today in the American Heart Association's peer-reviewed journals Circulation and Hypertension, and in JACC, the flagship journal of the American College of Cardiology.

14 Aug 2025

Engineered CD40 antibody shrinks tumors and induces remission

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment.

14 Aug 2025

Diabetes drugs linked to higher risk of rare optic nerve damage

...

14 Aug 2025

Genicular artery embolization relieves chronic knee pain caused by osteoarthritis

A procedure performed under mild sedation in less than two hours by an interventional radiologist relieves chronic knee pain caused by osteoarthritis, an NYU Langone Health study shows.

14 Aug 2025

Llama-derived nanobody VHH21 destroys the spike-trimer of SARS-CoV-2

Neutralizing antibodies that merely block receptor binding are losing ground against heavily mutated SARS-CoV-2 Omicron sub-variants.

14 Aug 2025

Research shows GLP-1 drugs safeguard vision despite small retinopathy risk

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, including a reduced risk of blindness. Patients with existing retinopathy on these drugs also needed fewer invasive eye treatments over two years.

13 Aug 2025

Pregabalin raises heart failure risk in older adults compared to gabapentin, study finds

A large Medicare cohort study found that older adults prescribed pregabalin had a significantly higher risk of developing heart failure compared to those prescribed gabapentin. The elevated risk was most pronounced in individuals with pre-existing cardiovascular disease, especially women and White patients.

13 Aug 2025

New computational tool enhances CAR T cell therapy for hard-to-treat cancers

A computational approach by St. Jude Children's Research Hospital scientists promises to make designing T cell-based immunotherapies that target two cancer-related antigens at the same time far easier and faster.

13 Aug 2025

New compound shows promise against aromatase inhibitor-resistant breast cancer

A new research paper was published in Volume 16 of Oncotarget on July 29, 2025, titled "PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion."

13 Aug 2025

Study supports pre-surgery use of GLP-1 RAs for weight reduction

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of surgical complications linked to their obesity, a new study reveals.

12 Aug 2025

Love hormone oxytocin found to be critical for the formation of friendships

A new UC Berkeley study shows that the so-called love hormone, oxytocin, is also critical for the formation of friendships.

12 Aug 2025

Cancer cells hide inside bone marrow fibroblasts to resist treatment

In a recently published study, researchers at Fox Chase Cancer Center revealed for the first time that cancer cells can evade anti-cancer drugs by entering and surviving within bone marrow fibroblasts, a phenomenon they describe as "cell-in-cell."

12 Aug 2025

Old Parkinson's medication offers new hope for tuberculosis treatment

A medication developed in the 1950s to treat Parkinson's disease may offer a powerful new tool in the fight against tuberculosis (TB), according to new research from the University of British Columbia.

12 Aug 2025

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward pathways, revealing targets for next-generation anti-obesity drugs. This review highlights the interplay between neuroendocrine circuits, neuroplasticity, and pharmacotherapy for durable, non-aversive weight loss.

11 Aug 2025

RSPO2 gene identified as key driver in metastatic prostate cancer

A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled "Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer."

11 Aug 2025

Study establishes a causal link between mitochondrial dysfunction and neurodegenerative diseases

Mitochondria, the tiny organelles without which our bodies would be deprived of energy, are gradually revealing their mysteries.

11 Aug 2025

AI model can design optimal drug candidates without any prior molecular data

Traditional drug development methods involve identifying a target protein (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) that could bind to that protein and block its function.

11 Aug 2025

New imaging technique reveals how antibodies reshape cancer cell receptors

A new study shows how the single-molecule organization of receptors in a cellular context determines the function of antibodies, opening up new pathways for the development of cancer immunotherapies.

11 Aug 2025

Lauric acid could be a key cancer-fighting compound in coconut oil

Virgin coconut oil and lauric acid show promise in inhibiting cancer cell growth and mitigating chemotherapy toxicity, paving the way for future therapies.

11 Aug 2025

Early clinical trial supports MASL as a targeted oral cancer treatment

Rowan University and Sentrimed, a clinical-stage biopharmaceutical company focused on developing safer, orally dosed oncology therapies, today announced results from a National Cancer Institute (NCI) funded clinical trial evaluating MASL in patients with oral squamous cell carcinoma (OSCC).

8 Aug 2025